Resource impact statement
Cancer Drugs Fund technology
NICE has recommended axicabtagene ciloleucel for use within the Cancer Drugs Fund for treating diffuse large B‑cell lymphoma and primary mediastinal B‑cell lymphoma after 2 or more systemic therapies.
Axicabtagene ciloleucel will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Kite Pharma have a commercial access agreement that makes axicabtagene ciloleucel available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of this recommendation will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires, February 2022, or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) – a new deal for patients, taxpayers and industry.
It is estimated that around 200 people per year with recurring large cell lymphoma are eligible for treatment with axicabtagene ciloleucel.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 23 January 2019